NEW YORK, NY / ACCESSWIRE / February 1, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL). Investors who purchased Anavex shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/avxl.
The investigation concerns whether Anavex and certain of its officers and/or directors have violated federal securities laws.
On February 1, 2022, Anavex issued a press release announcing that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. However, following the publication of the release, several posts on social media noted that the primary and secondary endpoints had been recently changed. For example, one post stated that "Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, allowing it to claim success when the drug most likely failed." On this news, Anavex's stock price fell sharply during intraday trading on February 1, 2022.
If you are aware of any facts relating to this investigation or purchased Anavex shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/avxl. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC